These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16729726)

  • 1. Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease.
    Rishton GM; LaBonte K; Williams AJ; Kassam K; Kolovanov E
    Curr Opin Drug Discov Devel; 2006 May; 9(3):303-13. PubMed ID: 16729726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secretases as therapeutic targets for the treatment of Alzheimer's disease].
    Dejaegere T; de Strooper B
    Verh K Acad Geneeskd Belg; 2004; 66(1):29-58; discussion 58-9. PubMed ID: 15074081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the development of gamma-secretase inhibitors.
    Josien H
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):513-25. PubMed ID: 12197309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Searching for the most effective screening system to identify cell-active inhibitors of beta-secretase.
    Middendorp O; Lüthi U; Hausch F; Barberis A
    Biol Chem; 2004 Jun; 385(6):481-5. PubMed ID: 15255179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Substituted gem-cyclohexane sulfone based gamma-secretase inhibitors for Alzheimer's disease: conformational analysis and biological activity.
    Jelley RA; Elliott J; Gibson KR; Harrison T; Beher D; Clarke EE; Lewis HD; Shearman M; Wrigley JD
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3839-42. PubMed ID: 16682202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.
    Roher AE; Kokjohn TA
    Alzheimers Dement; 2009 Sep; 5(5):437-8. PubMed ID: 19751925
    [No Abstract]   [Full Text] [Related]  

  • 7. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." The blood-brain barrier: a physical and conceptual challenge.
    Hachinski V; Lee TY
    Alzheimers Dement; 2009 Sep; 5(5):435-6. PubMed ID: 19751924
    [No Abstract]   [Full Text] [Related]  

  • 8. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma.
    Poduslo JF; Curran GL; Kumar A; Frangione B; Soto C
    J Neurobiol; 1999 Jun; 39(3):371-82. PubMed ID: 10363910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core.
    Lewis SJ; Smith AL; Neduvelil JG; Stevenson GI; Lindon MJ; Jones AB; Shearman MS; Beher D; Clarke E; Best JD; Peachey JE; Harrison T; Castro JL
    Bioorg Med Chem Lett; 2005 Jan; 15(2):373-8. PubMed ID: 15603957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
    Silvestri R
    Med Res Rev; 2009 Mar; 29(2):295-338. PubMed ID: 18651582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of tetramic and tetronic acids as beta-secretase inhibitors.
    Larbig G; Schmidt B
    J Comb Chem; 2006; 8(4):480-90. PubMed ID: 16827559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling Alzheimer's. Scientists are close to figuring out how the disorder destroys brains. But will their knowledge save lives?
    Gorman C
    Time; 2000 Jul; 156(2):98-9. PubMed ID: 10977415
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
    Roney C; Kulkarni P; Arora V; Antich P; Bonte F; Wu A; Mallikarjuana NN; Manohar S; Liang HF; Kulkarni AR; Sung HW; Sairam M; Aminabhavi TM
    J Control Release; 2005 Nov; 108(2-3):193-214. PubMed ID: 16246446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease: from pathology to therapeutic approaches.
    Jakob-Roetne R; Jacobsen H
    Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights for predicting blood-brain barrier penetration of CNS targeted molecules using QSPR approaches.
    Fan Y; Unwalla R; Denny RA; Di L; Kerns EH; Diller DJ; Humblet C
    J Chem Inf Model; 2010 Jun; 50(6):1123-33. PubMed ID: 20578728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomedicine. Avoiding collateral damage in Alzheimer's disease treatment.
    Glabe C
    Science; 2006 Oct; 314(5799):602-3. PubMed ID: 17068248
    [No Abstract]   [Full Text] [Related]  

  • 18. Aryl sulfones: a new class of gamma-secretase inhibitors.
    Teall M; Oakley P; Harrison T; Shaw D; Kay E; Elliott J; Gerhard U; Castro JL; Shearman M; Ball RG; Tsou NN
    Bioorg Med Chem Lett; 2005 May; 15(10):2685-8. PubMed ID: 15863342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options in Alzheimer's disease.
    Moreira PI; Zhu X; Nunomura A; Smith MA; Perry G
    Expert Rev Neurother; 2006 Jun; 6(6):897-910. PubMed ID: 16784412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.